The safety of intranasal steroids

被引:84
作者
Benninger, MS
Ahmad, N
Marple, BF
机构
[1] Henry Ford Hosp, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA
[2] Univ Texas, SW Med Ctr, SW Med Sch, Dept Otolaryngol, Houston, TX 77030 USA
关键词
D O I
10.1016/j.otohns.2003.10.001
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The increasing use of intranasal steroids in the management of allergic rhinitis reflects their efficacy, tolerability, and safety. However, issues related to the safety of intranasal steroids continue to generate debate and confusion among clinicans. Consequently, there is often reluctance and uncertainty in prescribing these effective agents for the treatment of perennial and seasonal allergic rhinitis. Issues of particular concern are whether intranasal steroids adversely affect various homeostatic systems, influence growth and bone metabolism, and compromise ocular function. Furthermore, the expanding role of intranasal steroids in the pediatric, geriatric, and postmenopausal populations has raised concerns that these agents may result in a steroid burden that more readily causes adverse effects. An extensive review of the literature overwhelmingly supports the assertion that intranasal steroids are safe in prescribed doses and should allay the misconceptions regarding their appropriate use in the management of allergic rhinitis.
引用
收藏
页码:739 / 750
页数:12
相关论文
共 54 条
[1]  
*AAAAI, 2001, ALL REP, V2
[2]   Systemic effects of intranasal steroids: An endocrinologist's perspective [J].
Allen, DB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (04) :S179-S190
[3]  
Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407
[4]  
Barnes PJ, 1996, J ALLERGY CLIN IM S3, V26, P18
[5]   Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children [J].
Boner, AL .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (01) :S32-S39
[6]   EFFECTS OF LONG-TERM USE OF HIGH-DOSE INHALED STEROIDS ON BONE-DENSITY AND CALCIUM-METABOLISM [J].
BOULET, LP ;
GIGUERE, MC ;
MILOT, J ;
BROWN, J .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (05) :796-803
[7]   Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children [J].
Brannan, MD ;
Herron, JM ;
Affrime, MB .
CLINICAL THERAPEUTICS, 1997, 19 (06) :1330-1339
[8]   LACK OF HYPOTHALAMIC-PITUITARY-ADRENAL AXIS SUPPRESSION WITH ONCE-DAILY OR TWICE-DAILY BECLOMETHASONE DIPROPIONATE AQUEOUS NASAL SPRAY ADMINISTERED TO PATIENTS WITH ALLERGIC RHINITIS [J].
BRANNAN, MD ;
HERRON, JM ;
REIDENBERG, P ;
AFFRIME, MB .
CLINICAL THERAPEUTICS, 1995, 17 (04) :637-647
[9]  
Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62
[10]  
Brannan MD, 1997, ANN ALLERG ASTHMA IM, V78, P154